The original success of Sildenafil undeniably reshaped the drug landscape, but investing in companies strongly reliant on generic versions presents a challenging picture. Although early returns were substantial, the end of patents and the rise of less expensive alternatives have weakened market share. Therefore, a thorough assessment of current fin